Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease.
Kupffer cells
alcohol related liver disease
alcoholic steatohepatitis
dimethyl fumarate
intestinal microbiota
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
16
01
2020
revised:
25
03
2020
accepted:
14
04
2020
pubmed:
20
4
2020
medline:
22
6
2021
entrez:
20
4
2020
Statut:
ppublish
Résumé
Alcohol-related liver disease (ALD) comprises different liver disorders which impose a health care issue. ALD and particularly alcoholic steatohepatitis, an acute inflammatory condition, cause a substantial morbidity and mortality as effective treatment options remain elusive. Inflammation in ALD is fuelled by macrophages (Kupffer cells [KCs]) which are activated by intestinal pathogen associated molecular patterns, eg lipopolysaccharide (LPS), disseminated beyond a defective intestinal barrier. We hypothesized that the immunomodulator dimethyl-fumarate (DMF), which is approved for the treatment of human inflammatory conditions such as multiple sclerosis or psoriasis, ameliorates the course of experimental ALD. Dimethyl-fumarate or vehicle was orally administered to wild-type mice receiving a Lieber-DeCarli diet containing 5% ethanol for 15 days. Liver injury, steatosis and inflammation were evaluated by histology, biochemical- and immunoassays. Moreover, we investigated a direct immunosuppressive effect of DMF on KCs and explored a potential impact on ethanol-induced intestinal barrier disruption. Dimethyl-fumarate protected against ethanol-induced hepatic injury, steatosis and inflammation in mice. Specifically, we observed reduced hepatic triglyceride and ALT accumulation, reduced hepatic expression of inflammatory cytokines (Tnf-α, Il-1β, Cxcl1) and reduced abundance of neutrophils and macrophages in ethanol-fed and DMF-treated mice when compared to vehicle. DMF protected against ethanol-induced barrier disruption and abrogated systemic LPS concentration. In addition, DMF abolished LPS-induced cytokine responses of KCs. Dimethyl-fumarate counteracts ethanol-induced barrier dysfunction, suppresses inflammatory responses of KCs and ameliorates hepatic inflammation and steatosis, hallmarks of experimental ALD. Our data indicates that DMF treatment might be beneficial in human ALD and respective clinical trials are eagerly awaited.
Sections du résumé
BACKGROUND & AIMS
Alcohol-related liver disease (ALD) comprises different liver disorders which impose a health care issue. ALD and particularly alcoholic steatohepatitis, an acute inflammatory condition, cause a substantial morbidity and mortality as effective treatment options remain elusive. Inflammation in ALD is fuelled by macrophages (Kupffer cells [KCs]) which are activated by intestinal pathogen associated molecular patterns, eg lipopolysaccharide (LPS), disseminated beyond a defective intestinal barrier. We hypothesized that the immunomodulator dimethyl-fumarate (DMF), which is approved for the treatment of human inflammatory conditions such as multiple sclerosis or psoriasis, ameliorates the course of experimental ALD.
METHODS
Dimethyl-fumarate or vehicle was orally administered to wild-type mice receiving a Lieber-DeCarli diet containing 5% ethanol for 15 days. Liver injury, steatosis and inflammation were evaluated by histology, biochemical- and immunoassays. Moreover, we investigated a direct immunosuppressive effect of DMF on KCs and explored a potential impact on ethanol-induced intestinal barrier disruption.
RESULTS
Dimethyl-fumarate protected against ethanol-induced hepatic injury, steatosis and inflammation in mice. Specifically, we observed reduced hepatic triglyceride and ALT accumulation, reduced hepatic expression of inflammatory cytokines (Tnf-α, Il-1β, Cxcl1) and reduced abundance of neutrophils and macrophages in ethanol-fed and DMF-treated mice when compared to vehicle. DMF protected against ethanol-induced barrier disruption and abrogated systemic LPS concentration. In addition, DMF abolished LPS-induced cytokine responses of KCs.
CONCLUSIONS
Dimethyl-fumarate counteracts ethanol-induced barrier dysfunction, suppresses inflammatory responses of KCs and ameliorates hepatic inflammation and steatosis, hallmarks of experimental ALD. Our data indicates that DMF treatment might be beneficial in human ALD and respective clinical trials are eagerly awaited.
Identifiants
pubmed: 32306456
doi: 10.1111/liv.14483
pmc: PMC7383968
doi:
Substances chimiques
Dimethyl Fumarate
FO2303MNI2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610-1619Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Gut. 2018 May;67(5):891-901
pubmed: 28550049
Expert Rev Neurother. 2015 Apr;15(4):339-46
pubmed: 25800129
Brain Nerve. 2017 Sep;69(9):1041-1046
pubmed: 28900067
Biochem Pharmacol. 2016 Jul 15;112:37-49
pubmed: 27184504
J Hepatol. 2015 Apr;62(1 Suppl):S38-46
pubmed: 25920088
J Hepatol. 2016 Apr;64(4):872-80
pubmed: 26682726
World J Hepatol. 2011 May 27;3(5):108-13
pubmed: 21731902
Inflamm Bowel Dis. 2015 Jun;21(6):1297-305
pubmed: 25901973
Eur J Immunol. 2008 Sep;38(9):2438-50
pubmed: 18792400
J Immunol. 2019 May 1;202(9):2737-2746
pubmed: 30885957
Hepatology. 2009 Aug;50(2):638-44
pubmed: 19575462
Alcohol Clin Exp Res. 2005 Dec;29(12 Suppl):246S-50S
pubmed: 16385231
ASN Neuro. 2011 Apr 07;3(2):
pubmed: 21382015
Hepatology. 2006 May;43(5):989-1000
pubmed: 16628628
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4777-82
pubmed: 27078105
Mol Cell Proteomics. 2019 Mar;18(3):504-519
pubmed: 30587509
Cell Immunol. 2014 Sep-Oct;291(1-2):41-8
pubmed: 24726741
J Neuroimmunol. 2015 Jun 15;283:74-85
pubmed: 26004161
Cell Mol Immunol. 2016 May;13(3):316-27
pubmed: 26908374
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 26;6(1):e517
pubmed: 30568995
Exp Mol Pathol. 1991 Oct;55(2):196-202
pubmed: 1936215
Am J Gastroenterol. 1999 Jan;94(1):200-7
pubmed: 9934756
Am J Gastroenterol. 1994 Dec;89(12):2205-11
pubmed: 7977243
World J Gastroenterol. 2017 Jul 7;23(25):4508-4516
pubmed: 28740339
Gastroenterology. 2014 May;146(5):1231-9.e1-6
pubmed: 24440674
Hepatology. 2008 Oct;48(4):1224-31
pubmed: 18792393
Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4(1):24-34
pubmed: 17203086
CNS Neurosci Ther. 2019 Sep;25(9):995-1005
pubmed: 31066225
J Exp Med. 2011 Jul 4;208(7):1367-76
pubmed: 21708926
Front Immunol. 2016 Nov 29;7:538
pubmed: 27965666
Cell Metab. 2006 Jul;4(1):13-24
pubmed: 16814729
N Engl J Med. 2000 Nov 16;343(20):1467-76
pubmed: 11078773
J Hepatol. 2011 Nov;55(5):1159-61
pubmed: 21723837
Br J Dermatol. 2003 Aug;149(2):363-9
pubmed: 12932244
Alcohol Clin Exp Res. 2001 Jun;25(6 Suppl):51S-4S
pubmed: 11410742
Int Immunol. 2014 Sep;26(9):509-15
pubmed: 24821262
J Hepatol. 2013 Jul;59(1):160-8
pubmed: 23511777
Drugs. 2018 Jan;78(1):123-130
pubmed: 29236231
Liver Int. 2020 Jul;40(7):1610-1619
pubmed: 32306456
Results Immunol. 2014 Aug 23;4:68-74
pubmed: 25379377
Cell. 2013 Jun 6;153(6):1239-51
pubmed: 23746840
Nat Protoc. 2013 Mar;8(3):627-37
pubmed: 23449255
J Pharmacol Exp Ther. 2012 Apr;341(1):274-84
pubmed: 22267202
Cell Metab. 2014 Jul 1;20(1):61-72
pubmed: 24930970
Hepatology. 1986 Mar-Apr;6(2):252-62
pubmed: 3007318
Cell Mol Immunol. 2014 May;11(3):224-31
pubmed: 24633014
Science. 2018 Apr 27;360(6387):449-453
pubmed: 29599194
J Invest Dermatol. 2016 Jan;136(1):117-26
pubmed: 26763431
Hepatology. 2013 Nov;58(5):1814-23
pubmed: 23532958
Clin Liver Dis. 2005 Feb;9(1):37-53
pubmed: 15763228